GlaucomaNCT07145073
Repetitive Transcranial Alternating Current Stimulation (rtACS) for the Treatment of Optic Neuropathies
A study testing DC-Stimulator MC in people with Glaucoma, run by National Taiwan University Hospital at 1 site in Taiwan.
Trial summary
The goal of this study is to see whether repeated transcranial alternating current stimulation can activate impaired retinal ganglion cells and improve both structural and functional outcomes in patients with glaucoma. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Glaucoma
- What is being tested?
- DC-Stimulator MC
- Type of treatment
- Medical device
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 188 participants
- Where
- 1 siteTaiwan
- Study dates
- 26 Jan 2026to 31 Dec 2028
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Participant must be at least 18.
- Clinical diagnosis of glaucoma, with Humphrey Visual Field 24-2 mean deviation (MD) between -22 dB and -5 dB, and Visual Field Index (VFI) between 10% and 90%. The visual field test at screening must meet the following reliability indices:
- Fixation losses (FL) ≤ 33%
- False-negative rate (FNR) ≤ 20%
- False-positive rate (FPR) ≤ 20% At initial screening, the difference in MD between two consecutive visual field tests must be less than 2 dB.
- Best-corrected visual acuity (BCVA) ≥ 0.2 in the worse eye selected for stimulation treatment.
Show all 11Show fewer
- If a participant has two eyes meeting study criteria, one eye will be randomly selected by computer for study participation.
- In the opinion of the investigator the participant's eye pressure must be clinically stable.
- Participant must has the ability to comply with the requirements of the study and complete the schedule of events.
- Participant must understand and sign the informed consent. If the participant's vision is impaired to the point where he/she cannot read the informed consent document, the document will be read to the participant in its entirety.
- Optical coherence tomography (OCT) imaging shows measurable changes in either peripapillary retinal nerve fiber layer (RNFL) thickness or macular ganglion cell-inner plexiform layer thickness.
Who cannot join
- History of ocular herpes.
- Pathological nystagmus.
- Retinal disease sufficient to affect vision.
- Corneal opacity affecting vision.
- Cataract affecting vision.
- Uveitis or other intraocular inflammatory disease.
Show all 19Show fewer
- Implanted electronic devices such as a pacemaker.
- Rheumatologic or autoimmune disease.
- Brain tumor or intracranial magnetic metallic implants.
- History of epilepsy.
- Periocular skin lesions.
- Anxiety with Geriatric Anxiety Scale score > 12.
- History of claustrophobia.
- Participation in another clinical trial within the past 3 months involving medication or training that could affect the eyes.
- Physical or mental conditions that may increase the risk of participation or interfere with study assessments (e.g., dementia).
- Previous ocular electrical stimulation treatment or visual training study within the past 12 months.
- Uncontrolled hypertension or diabetes.
- Pregnant or breastfeeding.
- History of craniotomy, burr hole surgery, head trauma, intracranial tumor, vascular malformation, or intracranial surgery.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Yu-Cen Ma contact
Taiwan1 site, 1 recruiting
- Recruiting
National Taiwan University Hospital
Taipei, Hawaii, 100
Chien-Chia Su, MD., PhD, 886972653340, chienchiasu@ntu.edu.tw
Yu-Cen Ma, MS, 886903028820, s431075656@gmail.com
About this study
Official title: Repetitive Transcranial Alternating Current Stimulation(rtACS) for the Treatment of Optic Neuropathies
The goal of this study is to see whether repeated transcranial alternating current stimulation can activate impaired retinal ganglion cells and improve both structural and functional outcomes in patients with glaucoma.
- Conditions
- Glaucoma
- Being tested
- DC-Stimulator MC
- Keywords
- Glaucoma, electrical stimulation
- Medical subject headings
- Glaucoma
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
DC-Stimulator MCDevice
Experimental：Participants will receive 10 days of repeated transcranial alternating current stimulation treatment in hospital.
DC-Stimulator MCDevice
Sham Comparator：Participants will receive 10 days of repeated transcranial alternating current stimulation treatment (no active stimulation) in hospital.
| Study group | Role | What they receive |
|---|---|---|
| Repetitive Transcranial Alternating Current Stimulation treatment | Experimental | Participants will receive 10 days of repeated transcranial alternating current stimulation in hospital. Receives: Device: DC-Stimulator MC |
| Sham Repetitive Transcranial Alternating Current Stimulation | Sham comparator | Participants will receive 10 days of repeated transcranial alternating current stimulation treatment (no active stimulation) in hospital. Receives: Device: DC-Stimulator MC |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in visual field mean deviation (MD) from baseline to post-treatment
Visual field testing will be performed with the Humphrey field analyzer
Measured: From treatment initiation to 26 days after treatment initiation
Secondary outcomes (68)
Change in visual field mean deviation (MD) from baseline to post-treatment
Visual field testing will be performed with the Humphrey field analyzer
Measured: From treatment initiation to 12 days after treatment initiation
Change in visual field mean deviation (MD) from baseline to post-treatment
Visual field testing will be performed with the Humphrey field analyzer
Measured: From treatment initiation to 19 days after treatment initiation
Change in visual field mean deviation (MD) from baseline to post-treatment
Visual field testing will be performed with the Humphrey field analyzer
Measured: From treatment initiation to 166 days after treatment initiation
Change in sensitivity at each of the 52 test points in the 24-2 visual field from baseline to post-treatment
Measured: From treatment initiation to 26 days after treatment initiation
Change in targeted mean deviation from baseline to post-treatment
Measured: From treatment initiation to 12 days after treatment initiation
Change in targeted mean deviation from baseline to post-treatment
Measured: From treatment initiation to 19 days after treatment initiation
Change in targeted mean deviation from baseline to post-treatment
Measured: From treatment initiation to 26 days after treatment initiation
Change in targeted mean deviation from baseline to post-treatment
Measured: From treatment initiation to 166 days after treatment initiation
Visual function analysis from baseline to post-treatment
Visual acuity measured by Landolt C Chart.
Measured: From treatment initiation to 5 days after treatment initiation
Visual function analysis from baseline to post-treatment
Contrast sensitivity measured by CSV-1000
Measured: From treatment initiation to 5 days after treatment initiation
Visual function analysis from baseline to post-treatment
Contrast sensitivity measured by Pelli-Robson Contrast Sensitivity Chart
Measured: From treatment initiation to 5 days after treatment initiation
Visual function analysis from baseline to post-treatment
Contrast sensitivity measured by MARS Contrast Sensitivity Chart
Measured: From treatment initiation to 5 days after treatment initiation
Visual function analysis from baseline to post-treatment
Color vision measured by HRR pseudoisochromatic test
Measured: From treatment initiation to 5 days after treatment initiation
Visual function analysis from baseline to post-treatment
Continuous Chinese reading acuity measured by Paragraph Chinese Reading Acuity Test (P-CRAT)
Measured: From treatment initiation to 5 days after treatment initiation
Visual function analysis from baseline to post-treatment
Visual acuity measured by Landolt C Chart
Measured: From treatment initiation to 12 days after treatment initiation
Visual function analysis from baseline to post-treatment
Contrast sensitivity measured by CSV-1000
Measured: From treatment initiation to 12 days after treatment initiation
Visual function analysis from baseline to post-treatment
Contrast sensitivity measured by Pelli-Robson Contrast Sensitivity Chart
Measured: From treatment initiation to 12 days after treatment initiation
Visual function analysis from baseline to post-treatment
Contrast sensitivity measured by MARS Contrast Sensitivity Chart
Measured: From treatment initiation to 12 days after treatment initiation
Visual function analysis from baseline to post-treatment
Color vision measured by HRR pseudoisochromatic test
Measured: From treatment initiation to 12 days after treatment initiation
Visual function analysis from baseline to post-treatment
Continuous Chinese reading acuity measured by Paragraph Chinese Reading Acuity Test (P-CRAT)
Measured: From treatment initiation to 12 days after treatment initiation]
Visual function analysis from baseline to post-treatment
Visual acuity measured by Landolt C Chart
Measured: From treatment initiation to 26 days after treatment initiation
Visual function analysis from baseline to post-treatment
Contrast sensitivity measured by CSV-1000
Measured: From treatment initiation to 26 days after treatment initiation
Visual function analysis from baseline to post-treatment
Contrast sensitivity measured by Pelli-Robson Contrast Sensitivity Chart
Measured: From treatment initiation to 26 days after treatment initiation
Visual function analysis from baseline to post-treatment
Contrast sensitivity measured by MARS Contrast Sensitivity Chart
Measured: From treatment initiation to 26 days after treatment initiation
Visual function analysis from baseline to post-treatment
Color vision measured by HRR pseudoisochromatic test
Measured: From treatment initiation to 26 days after treatment initiation
Visual function analysis from baseline to post-treatment
Continuous Chinese reading acuity measured by Paragraph Chinese Reading Acuity Test (P-CRAT)
Measured: From treatment initiation to 26 days after treatment initiation
Visual function analysis from baseline to post-treatment
Visual acuity measured by Landolt C Chart
Measured: From treatment initiation to 166 days after treatment initiation
Visual function analysis from baseline to post-treatment
Contrast sensitivity measured by CSV-1000
Measured: From treatment initiation to 166 days after treatment initiation
Visual function analysis from baseline to post-treatment
Contrast sensitivity measured by Pelli-Robson Contrast Sensitivity Chart
Measured: From treatment initiation to 166 days after treatment initiation
Visual function analysis from baseline to post-treatment
Contrast sensitivity measured by MARS Contrast Sensitivity Chart
Measured: From treatment initiation to 166 days after treatment initiation
Visual function analysis from baseline to post-treatment
Color vision measured by HRR pseudoisochromatic test
Measured: From treatment initiation to 166 days after treatment initiation
Visual function analysis from baseline to post-treatment
Continuous Chinese reading acuity measured by Paragraph Chinese Reading Acuity Test (P-CRAT)
Measured: From treatment initiation to 166 days after treatment initiation
Quality of life analysis from baseline to post-treatment
Vision-related quality of life assessed using the National Eye Institute 25-Item Visual Function Questionnaire (NEI VFQ-25). Scores are converted to a 0-100 scale, where higher scores indicate better vision-related quality of life.
Measured: From treatment initiation to 12 days after treatment initiation
Quality of life analysis from baseline to post-treatment
Health status assessed using the 36-Item Short Form Health Survey (SF-36). Scores for each domain and the overall score range from 0 to 100, where higher scores indicate better health status.
Measured: From treatment initiation to 12 days after treatment initiation
Quality of life analysis from baseline to post-treatment
Mobility in daily life assessed using the Mobility questionnaire. This questionnaire focuses on difficulties related to mobility and driving. Scores are reported on a 0-172 scale, where higher scores indicate greater difficulty with mobility and driving in daily life.
Measured: From treatment initiation to 12 days after treatment initiation
Quality of life analysis from baseline to post-treatment
Vision-related quality of life assessed using the National Eye Institute 25-Item Visual Function Questionnaire (NEI VFQ-25). Scores are converted to a 0-100 scale, where higher scores indicate better vision-related quality of life.
Measured: From treatment initiation to 166 days after treatment initiation
Quality of life analysis from baseline to post-treatment
Health status assessed using the 36-Item Short Form Health Survey (SF-36). Scores for each domain and the overall score range from 0 to 100, where higher scores indicate better health status.
Measured: From treatment initiation to 166 days after treatment initiation
Quality of life analysis from baseline to post-treatment
Mobility in daily life assessed using the Mobility questionnaire. This questionnaire focuses on difficulties related to mobility and driving. Scores are reported on a 0-172 scale, where higher scores indicate greater difficulty with mobility and driving in daily life.
Measured: From treatment initiation to 166 days after treatment initiation
Optical coherence tomography (OCT) analysis from baseline to post-treatment
Peripapillary retinal nerve fiber layer (RNFL) thickness (μm)
Measured: From treatment initiation to 12 days after treatment initiation
Optical coherence tomography (OCT) analysis from baseline to post-treatment
Macular ganglion cell-inner plexiform layer thickness (μm)
Measured: From treatment initiation to 12 days after treatment initiation
Optical coherence tomography (OCT) analysis from baseline to post-treatment
Optic nerve head cup-to-disc ratio (%)
Measured: From treatment initiation to 12 days after treatment initiation
Optical coherence tomography (OCT) analysis from baseline to post-treatment
Peripapillary retinal nerve fiber layer (RNFL) thickness (μm)
Measured: From treatment initiation to 26 days after treatment initiation
Optical coherence tomography (OCT) analysis from baseline to post-treatment
Macular ganglion cell-inner plexiform layer thickness (μm)
Measured: From treatment initiation to 26 days after treatment initiation
Optical coherence tomography (OCT) analysis from baseline to post-treatment
Optic nerve head cup-to-disc ratio (%)
Measured: From treatment initiation to 26 days after treatment initiation
Optical coherence tomography (OCT) analysis from baseline to post-treatment
Peripapillary retinal nerve fiber layer (RNFL) thickness (μm)
Measured: From treatment initiation to 166 days after treatment initiation
Optical coherence tomography (OCT) analysis from baseline to post-treatment
Macular ganglion cell-inner plexiform layer thickness (μm)
Measured: From treatment initiation to 166 days after treatment initiation
Optical coherence tomography (OCT) analysis from baseline to post-treatment
Optic nerve head cup-to-disc ratio (%)
Measured: From treatment initiation to 166 days after treatment initiation
Optical coherence tomography angiography(OCT-A) analysis from baseline to post-treatment
Peripapillary vessel density
Measured: From treatment initiation to 12 days after treatment initiation
Optical coherence tomography angiography(OCT-A) analysis from baseline to post-treatment
capillary density
Measured: From treatment initiation to 12 days after treatment initiation
Optical coherence tomography angiography(OCT-A) analysis from baseline to post-treatment
Superficial density
Measured: From treatment initiation to 12 days after treatment initiation
Optical coherence tomography angiography(OCT-A) analysis from baseline to post-treatment
deep density
Measured: From treatment initiation to 12 days after treatment initiation
Optical coherence tomography angiography(OCT-A) analysis from baseline to post-treatment
foveal vessel density
Measured: From treatment initiation to 12 days after treatment initiation
Optical coherence tomography angiography(OCT-A) analysis from baseline to post-treatment
parafoveal vessel density
Measured: From treatment initiation to 12 days after treatment initiation
Optical coherence tomography angiography(OCT-A) analysis from baseline to post-treatment
Foveal avascular zone (FAZ)
Measured: From treatment initiation to 12 days after treatment initiation
Optical coherence tomography angiography(OCT-A) analysis from baseline to post-treatment
Peripapillary vessel density
Measured: From treatment initiation to 26 days after treatment initiation
Optical coherence tomography angiography(OCT-A) analysis from baseline to post-treatment
capillary density
Measured: From treatment initiation to 26 days after treatment initiation
Optical coherence tomography angiography(OCT-A) analysis from baseline to post-treatment
Superficial density
Measured: From treatment initiation to 26 days after treatment initiation
Optical coherence tomography angiography(OCT-A) analysis from baseline to post-treatment
deep density
Measured: From treatment initiation to 26 days after treatment initiation
Optical coherence tomography angiography(OCT-A) analysis from baseline to post-treatment
foveal vessel density
Measured: From treatment initiation to 26 days after treatment initiation
Optical coherence tomography angiography(OCT-A) analysis from baseline to post-treatment
parafoveal vessel density
Measured: From treatment initiation to 26 days after treatment initiation
Optical coherence tomography angiography(OCT-A) analysis from baseline to post-treatment
Foveal avascular zone (FAZ)
Measured: From treatment initiation to 26 days after treatment initiation
Optical coherence tomography angiography(OCT-A) analysis from baseline to post-treatment
Peripapillary vessel density
Measured: From treatment initiation to 166 days after treatment initiation
Optical coherence tomography angiography(OCT-A) analysis from baseline to post-treatment
capillary density
Measured: From treatment initiation to 166 days after treatment initiation
Optical coherence tomography angiography(OCT-A) analysis from baseline to post-treatment
Superficial density
Measured: From treatment initiation to 166 days after treatment initiation
Optical coherence tomography angiography(OCT-A) analysis from baseline to post-treatment
deep density
Measured: From treatment initiation to 166 days after treatment initiation
Optical coherence tomography angiography(OCT-A) analysis from baseline to post-treatment
foveal vessel density
Measured: From treatment initiation to 166 days after treatment initiation
Optical coherence tomography angiography(OCT-A) analysis from baseline to post-treatment
parafoveal vessel density
Measured: From treatment initiation to 166 days after treatment initiation
Optical coherence tomography angiography(OCT-A) analysis from baseline to post-treatment
Foveal avascular zone (FAZ)
Measured: From treatment initiation to 166 days after treatment initiation
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted28 Aug 2025
- Study start26 Jan 2026
- Primary completion31 Dec 2027 (estimated)
- Study completion31 Dec 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for GlaucomaStudies of the same condition, open and under way.
- More trials run by National Taiwan University HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 188 participants (estimated)
Sponsor and investigators
- Lead sponsor
- National Taiwan University Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07145073
- Sponsor's protocol ID
- 202409124DSE
- Status last verified
- Aug 2025
- First submitted
- 11 Aug 2025
- Last updated
- 30 Jan 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 30 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Repetitive Transcranial Alternating Current Stimulation(rtACS) for the Treatment of Optic Neuropathies
- ClinicalTrials.gov ID
- NCT07145073
- Acronym / sponsor ID
- 202409124DSE
- Conditions
- Glaucoma
- Keywords
- Glaucoma, electrical stimulation
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 188 participants (estimated)
- Lead sponsor
- National Taiwan University HospitalUniversity, hospital or other
- Study start
- 26 Jan 2026 (actual)
- Primary completion
- 31 Dec 2027 (estimated)
- Study completion
- 31 Dec 2028 (estimated)
- First posted
- 28 Aug 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this study is to see whether repeated transcranial alternating current stimulation can activate impaired retinal ganglion cells and improve both structural and functional outcomes in patients with glaucoma.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Repetitive Transcranial Alternating Current Stimulation treatment | Experimental | Device: DC-Stimulator MCParticipants will receive 10 days of repeated transcranial alternating current stimulation in hospital. |
| Sham Repetitive Transcranial Alternating Current Stimulation | Sham comparator | Device: DC-Stimulator MCParticipants will receive 10 days of repeated transcranial alternating current stimulation treatment (no active stimulation) in hospital. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (11 listed)
- Participant must be at least 18.
- Clinical diagnosis of glaucoma, with Humphrey Visual Field 24-2 mean deviation (MD) between -22 dB and -5 dB, and Visual Field Index (VFI) between 10% and 90%. The visual field test at screening must meet the following reliability indices:
- Best-corrected visual acuity (BCVA) ≥ 0.2 in the worse eye selected for stimulation treatment.
- If a participant has two eyes meeting study criteria, one eye will be randomly selected by computer for study participation.
- In the opinion of the investigator the participant's eye pressure must be clinically stable.
Key exclusion criteria (19 listed)
- History of ocular herpes.
- Pathological nystagmus.
- Retinal disease sufficient to affect vision.
- Corneal opacity affecting vision.
- Cataract affecting vision.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| DC-Stimulator MCExperimental：Participants will receive 10 days of repeated transcranial alternating current stimulation treatment in hospital. | Device | Repetitive Transcranial Alternating Current Stimulation treatment |
| DC-Stimulator MCSham Comparator：Participants will receive 10 days of repeated transcranial alternating current stimulation treatment (no active stimulation) in hospital. | Device | Sham Repetitive Transcranial Alternating Current Stimulation |
Primary outcome
Change in visual field mean deviation (MD) from baseline to post-treatment
Time frame: From treatment initiation to 26 days after treatment initiation
Visual field testing will be performed with the Humphrey field analyzer
68 secondary outcomes
Change in visual field mean deviation (MD) from baseline to post-treatment
Time frame: From treatment initiation to 12 days after treatment initiation
Change in visual field mean deviation (MD) from baseline to post-treatment
Time frame: From treatment initiation to 19 days after treatment initiation
Change in visual field mean deviation (MD) from baseline to post-treatment
Time frame: From treatment initiation to 166 days after treatment initiation
Change in sensitivity at each of the 52 test points in the 24-2 visual field from baseline to post-treatment
Time frame: From treatment initiation to 26 days after treatment initiation
Change in targeted mean deviation from baseline to post-treatment
Time frame: From treatment initiation to 12 days after treatment initiation
Change in targeted mean deviation from baseline to post-treatment
Time frame: From treatment initiation to 19 days after treatment initiation
Change in targeted mean deviation from baseline to post-treatment
Time frame: From treatment initiation to 26 days after treatment initiation
Change in targeted mean deviation from baseline to post-treatment
Time frame: From treatment initiation to 166 days after treatment initiation
Visual function analysis from baseline to post-treatment
Time frame: From treatment initiation to 5 days after treatment initiation
Visual function analysis from baseline to post-treatment
Time frame: From treatment initiation to 5 days after treatment initiation
Visual function analysis from baseline to post-treatment
Time frame: From treatment initiation to 5 days after treatment initiation
Visual function analysis from baseline to post-treatment
Time frame: From treatment initiation to 5 days after treatment initiation
Visual function analysis from baseline to post-treatment
Time frame: From treatment initiation to 5 days after treatment initiation
Visual function analysis from baseline to post-treatment
Time frame: From treatment initiation to 5 days after treatment initiation
Visual function analysis from baseline to post-treatment
Time frame: From treatment initiation to 12 days after treatment initiation
Visual function analysis from baseline to post-treatment
Time frame: From treatment initiation to 12 days after treatment initiation
Visual function analysis from baseline to post-treatment
Time frame: From treatment initiation to 12 days after treatment initiation
Visual function analysis from baseline to post-treatment
Time frame: From treatment initiation to 12 days after treatment initiation
Visual function analysis from baseline to post-treatment
Time frame: From treatment initiation to 12 days after treatment initiation
Visual function analysis from baseline to post-treatment
Time frame: From treatment initiation to 12 days after treatment initiation]
Visual function analysis from baseline to post-treatment
Time frame: From treatment initiation to 26 days after treatment initiation
Visual function analysis from baseline to post-treatment
Time frame: From treatment initiation to 26 days after treatment initiation
Visual function analysis from baseline to post-treatment
Time frame: From treatment initiation to 26 days after treatment initiation
Visual function analysis from baseline to post-treatment
Time frame: From treatment initiation to 26 days after treatment initiation
Visual function analysis from baseline to post-treatment
Time frame: From treatment initiation to 26 days after treatment initiation
Visual function analysis from baseline to post-treatment
Time frame: From treatment initiation to 26 days after treatment initiation
Visual function analysis from baseline to post-treatment
Time frame: From treatment initiation to 166 days after treatment initiation
Visual function analysis from baseline to post-treatment
Time frame: From treatment initiation to 166 days after treatment initiation
Visual function analysis from baseline to post-treatment
Time frame: From treatment initiation to 166 days after treatment initiation
Visual function analysis from baseline to post-treatment
Time frame: From treatment initiation to 166 days after treatment initiation
Visual function analysis from baseline to post-treatment
Time frame: From treatment initiation to 166 days after treatment initiation
Visual function analysis from baseline to post-treatment
Time frame: From treatment initiation to 166 days after treatment initiation
Quality of life analysis from baseline to post-treatment
Time frame: From treatment initiation to 12 days after treatment initiation
Quality of life analysis from baseline to post-treatment
Time frame: From treatment initiation to 12 days after treatment initiation
Quality of life analysis from baseline to post-treatment
Time frame: From treatment initiation to 12 days after treatment initiation
Quality of life analysis from baseline to post-treatment
Time frame: From treatment initiation to 166 days after treatment initiation
Quality of life analysis from baseline to post-treatment
Time frame: From treatment initiation to 166 days after treatment initiation
Quality of life analysis from baseline to post-treatment
Time frame: From treatment initiation to 166 days after treatment initiation
Optical coherence tomography (OCT) analysis from baseline to post-treatment
Time frame: From treatment initiation to 12 days after treatment initiation
Optical coherence tomography (OCT) analysis from baseline to post-treatment
Time frame: From treatment initiation to 12 days after treatment initiation
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 30 Jan 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Glaucoma
Recruiting
Implementing AI-based Glaucoma Screening Within Federally Qualified Health Centers
Glaucoma, Ocular Hypertension
Not yet recruiting
AI-Assisted vs Conventional Teleglaucoma Referral
Glaucoma
Recruiting
Brain Stimulation Effects on Orientation and Mobility Skills in Adults With Vision Impairment
Retinitis Pigmentosa (RP), Rod Cone Dystrophy
Recruiting
Automated Applanation Tonometry - Updated
Glaucoma, Glaucoma, Suspect
RecruitingPhase 2
A Phase 2a Study Comparing the Efficacy, Safety and Tolerability of Pregabalin Eye Drops Comparing With Timolol Eye Drops in Adults With Glaucoma or High Eye Pressure.
Primary Open - Angle Glaucoma (POAG), Ocular Hypertension (OHT)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Yu-Cen Ma contact
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing DC-Stimulator MC in people with Glaucoma, run by National Taiwan University Hospital at 1 site in Taiwan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 11 inclusion and 19 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 30 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Taiwan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Chien-Chia Su (+886 972653340, chienchiasu@ntu.edu.tw), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in visual field mean deviation (MD) from baseline to post-treatment (time frame: From treatment initiation to 26 days after treatment initiation). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Jan 2026.